BMS vs. Moderna vs. Pfizer: The RNA Platform Race

The Next Competitive Battlefield in Biopharma

Pharma is moving into a new phase of competition one shaped less by individual assets and more by the systems that generate them. For years, companies competed molecule by molecule, with each drug carrying its own risk, timeline, and commercial logic.

That model is giving way to something more scalable, as RNA has accelerated that transition. What began as a pandemic-driven validation has now become a strategic priority across the industry. RNA is not just another modality; it is a programmable approach to drug development.

The implication is profound, as competition is no longer about who has the best single product. It is about who builds the most effective platform to repeatedly produce high-value therapies.

Three companies illustrate how differently this is playing out.

• Moderna continues to double down on platform ownership.
• Pfizer is recalibrating its partnership-driven approach post-COVID—most notably through its long-standing collaboration with BioNTech to develop mRNA vaccines and therapeutics.
• Bristol Myers Squibb is investing to close a capability gap as it prepares for its next growth cycle, including its acquisition of Orbital Therapeutics, a next-generation RNA platform company.

For executives, these are not abstract strategies, they are signals of how the competitive landscape is being rewired in real time.

From Molecules to Learning Systems

RNA forces a shift in how value is created. Traditional pharma asks: does this molecule work? Platform-driven pharma asks: how quickly can we learn across many molecules and translate that learning into better outcomes?

The companies that win will be those that build the fastest design–test–learn loops. Each iteration generates data, each dataset improves the next design, and over time, that feedback loop compounds into a structural advantage.

This is where the strategic tension lies today. Most organizations are still built to optimize individual programs, not continuous learning systems.

RNA exposes that gap. It rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

Moderna: Doubling Down on Platform Leverage

Moderna enters this phase with a clear identity. It is not repositioning itself, it is extending what it has already built.

The COVID vaccine created both validation and expectations. Now the company is under pressure to demonstrate that its platform can scale beyond infectious disease into oncology, rare diseases, and personalized medicine.

Early signals, particularly in individualized cancer vaccines, are promising but not yet definitive. What distinguishes Moderna is not just its pipeline, but its accumulated learning.

Years of iteration in mRNA design, delivery, and manufacturing give it a head start that is difficult to replicate quickly. The question for executives watching Moderna is not whether it has capability—it clearly does—but whether that capability translates into sustained, diversified value.

If it does, Moderna will redefine what a platform-native biopharma company looks like. If it does not, it risks being seen as a pandemic-era outlier rather than a durable model.

Pfizer: Recalibrating After the Partnership Surge

Pfizer executed one of the most successful partnership strategies in industry history through its collaboration with BioNTech. Originally initiated in 2018 for mRNA-based influenza vaccines, the partnership rapidly scaled during COVID-19 into a global development, manufacturing, and commercialization alliance that produced one of the first approved mRNA vaccines.

The speed, scale, and global reach of that effort set a new benchmark. But the post-COVID environment looks different.

Revenue normalization, pipeline pressure, and a looming patent cliff are forcing a broader strategic reassessment. RNA remains important, but Pfizer’s position is more complex. It benefited from the platform without fully owning it.

That distinction now matters. As RNA expands into new therapeutic areas, Pfizer faces a choice: continue to rely on partnerships or build deeper internal capabilities.

Each path has trade-offs—partnerships offer flexibility and speed, whereas internal platforms offer control and long-term leverage.

If RNA platforms become central to long-term growth, deeper integration—including the possibility of acquisition—could emerge as a strategic option. That would shift Pfizer from a partner leveraging external innovation to a company with full control over a core platform capability.

For executives, Pfizer’s next moves will be closely watched not because of what it has already achieved, but how it chooses to evolve from here.

Bristol Myers Squibb: Positioning for the Next Growth Cycle

Bristol Myers Squibb is approaching RNA from a different starting point. The company’s strength in oncology and immunology remains clear, but it faces a familiar industry challenge: how to sustain growth as key assets mature.

This is particularly relevant for Opdivo (nivolumab), one of the company’s flagship immuno-oncology therapies, which is expected to face loss of exclusivity toward the end of the decade. As that revenue base comes under pressure, the need to build the next generation of growth drivers becomes more urgent.

RNA, in this context, is not simply an adjacent innovation, it is part of a broader effort to reshape the company’s future portfolio. Entering through acquisition reflects a deliberate attempt to build capability quickly rather than organically.

This is exemplified by its $1.5 billion acquisition of Orbital Therapeutics, a company developing a proprietary RNA platform combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design. Through this deal, BMS gains access not only to early-stage RNA therapies, including in vivo cell reprogramming approaches, but also to a scalable platform that can be applied across autoimmune disease, oncology, and next-generation vaccines.

The challenge is not strategic intent, it is execution. RNA platforms require integration across research, manufacturing, and clinical development.

They also require time to generate meaningful outputs. BMS is effectively compressing that timeline.

For executives, the key question is whether this approach can deliver both learning and value fast enough to influence the company’s next wave of growth. If it does, BMS strengthens its position in a platform-driven future. If not, the investment risks becoming another example of late-entry optionality.

Three Strategies, One Race

The contrast between these companies reflects three distinct philosophies. Moderna is building depth and compounding its advantage.

Pfizer is balancing speed with flexibility through partnerships while reassessing long-term control. BMS is investing through acquisition to ensure it is not left behind as the modality landscape evolves.

None of these strategies guarantees success, as the RNA race is still in its early stages. What will matter is not just the initial position, but how effectively each company adapts as the science—and the economics—continue to develop.

The Real Bottleneck: Delivery and Durability

Despite the momentum, two challenges continue to define the limits of RNA therapeutics: delivery and durability. Getting RNA to the right cells in a consistent, targeted way remains difficult.

Ensuring that its effects last long enough to be clinically meaningful is equally challenging. These are not incremental problems; they are foundational constraints that will determine how broadly RNA can be applied.

The companies that solve them will not just gain a competitive edge, they will expand the boundaries of what the platform can do.

What This Means for Pharmaceutical Executives

For leadership teams, the implications are immediate. RNA is not simply another line item in the pipeline, it is a strategic capability that intersects with manufacturing, data, regulatory strategy, and commercialization.

This raises a set of critical questions:

• Do we have a coherent RNA strategy, or are we reacting opportunistically?
• Are we building internal learning systems, or relying on external innovation?
• How does RNA integrate with our core therapeutic areas and long-term portfolio?

The answers will shape not just pipeline decisions, but organizational design and capital allocation over the next decade.

Conclusion

The RNA platform race will not be decided in the near term. It will unfold over years, shaped by scientific progress, execution discipline, and the ability to translate learning into scalable value.

One conclusion, however, is already emerging. In the next era of pharma, success will belong to companies that think less like product developers and more like learning organizations. Platforms will matter more than pipelines. The companies that internalize that shift early will define the structure of competition going forward.

For everyone else, the risk is not missing a single opportunity. It is missing the direction in which the industry is already moving.

About the Author

Thani Jambulingam, PhD, is a professor in food, pharma and healthcare at Erivan K. Haub School of Business, Saint Joseph’s University, Philadelphia. He is a pharma and healthcare strategist and his work focuses on AI-enabled decision frameworks, emerging technologies, and commercial strategy. He can reached at tjambuli@sju.edu.